| Literature DB >> 32951933 |
Kristi L Koenig1, Stephanie B Benjamin2, Christian K Beÿ3, Sue Dickinson4, Michelle Shores5.
Abstract
BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has contributed to an increase in intimate partner violence (IPV), posing challenges to health care providers who must protect themselves and others during sexual assault examinations. Victims of sexual assault encountered in prehospital and emergency department (ED) settings have legal as well as medical needs. A series of procedures must be carefully followed to facilitate forensic evidence collection and law enforcement investigation. A literature review detected a paucity of published guidance on the management of sexual assault patients in the ED, and no information specific to COVID-19.Entities:
Keywords: COVID-19; coronavirus; domestic violence; forensics; intimate partner violence; sexual assault; sexual assault examination; sexual assault guidelines; trauma-informed care
Year: 2020 PMID: 32951933 PMCID: PMC7498374 DOI: 10.1016/j.jemermed.2020.07.047
Source DB: PubMed Journal: J Emerg Med ISSN: 0736-4679 Impact factor: 1.484
Figure 1Model sexual assault guidelines from San Diego County, CA. The included San Diego County patient management guidelines were originally distributed in September 2019. BV = bacterial vaginosis; CDC = Centers for Disease Control and Prevention; CT = computed tomography; HBIG = hepatitis B immune globulin; HCG = human chorionic gonadotropin; Hep B = hepatitis B; HIV Ag/Ab = human immunodeficiency virus antigen/antibody; HPV = human papillomavirus; RN = registered nurse; STI = sexually transmitted infection.
Figure 2SAFET-I: Clinical Guidelines for the Management of Sexual Assault Patients in the Emergency Department. The SAFET-I framework is based on the San Diego County guidelines and consists of five main components: stabilization, alert system activation, forensic evidence consideration, expedited post-assault treatment, and trauma-informed care. CT = computed tomography, EMS = Emergency Medical Services, SART = Sexual Assault Response Team.
Centers for Disease Control and Prevention Post-Exposure Prophylaxis Recommendations
| Medication | Dose | Route | Frequency |
|---|---|---|---|
| Ceftriaxone plus | 250 mg | i.m. | Once |
| Azithromycin plus | 1g | p.o. | Once |
| Metronidazole or | 2 g | p.o. | Once |
| Tinidazole | 2 g | p.o. | Once |
i.m. = intramuscular; p.o. = per os.
Centers for Disease Control and Prevention Human Immunodeficiency Virus Post-Exposure Prophylaxis∗
| Medication | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Tenofovir disoproxil fumarate plus | 300 mg | p.o. | Once daily | 28 days |
| Emtricitabine plus | 200 mg | p.o. | Once daily | 28 days |
| Raltegravir or | 400 mg | p.o. | Twice daily | 28 days |
| Dolutegravir | 50 mg | p.o. | Once daily | 28 days |
p.o. = per os. ∗Preferred 28-day regimen for individuals ≥13 years, inclduing pregnant women, with creatinine clearance ≥60 mL/min. See full CDC guidelines for treatment variations.